25 September 2018
Visiongain has launched a new pharma report: Global Next-Generation Antibody Therapies Market Forecast 2018-2028: Antibody-Drug Conjugates, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments & ALPs, Biosimilar Antibodies.
Next-generation antibody therapies are becoming established treatments for haematological malignancies and solid tumours (phase 3) pipelines are relatively sparse, however, with most pipeline candidates in phase 1 or phase 2 of development. Growth will be rapid from the middle of the forecast period as new therapies are approved. New therapies will likely compete with currently marketed monoclonal antibodies, biosimilars, and novel small molecule drugs. Increasing collaboration between biotechnology and big pharma companies will drive pipeline development, which may result in the dominance of a small number of technology platforms, as seen for example in the market for antibody-drug conjugates.
The lead analyst of the report commented "Success for developers of next-generation antibody therapies will depend on a number of factors, including having a technology platform that offers some advantage over standard monoclonal antibodies, the ability to advance a novel therapy through proof of concept, and partnership opportunities with Big Pharma.
Products that offer superior or additional efficacy compared to currently available therapies will be needed in order to compete against existing therapies and the biosimilars that are expected to become available for these therapies in developed markets. Alternatively, targeting new indications and new antigens will expand the potential in the market."
Leading companies featured in the report include Amgen, Inc., GlaxoSmithKline (GSK), Kirin Holdings (Kyowa Hakko Kirin Co., Ltd.), Merck KGaA, Novartis AG, Pfizer, Inc., Roche, Sanofi, Seattle Genetics, Inc., Shire plc
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
In recent years, the IVD market has experienced increased consolidation among industry participants, with significant merger and acquisition (M&A) activity, especially among larger companies as they diversify and manoeuvre for stronger positions.
14 May 2019
Expected increases in the level of healthcare coverage will allow greater proportion of the population to be able to afford medical care, which is still mostly paid for out-of-pocket by patients, as a greater amount of people have health insurance to cover their medical expenses.
09 May 2019
The major drivers supporting the growth of the mRNA Vaccines and Therapeutics Market are rising adoption of personalized medicine for effective treatment, advantages offered by mRNA-based products, and rising funding by pharmaceutical companies and government organizations.
07 May 2019
The cancer treating drugs market will continue to grow over the next ten years.